Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus CAR-T in relapsed/refractory B-cell lymphoma
ChiCTR2400094102Phase 2Recruiting
- Sponsor
- Chengdu Shangjin Nanfu Hospital
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in mature B-cell lymphoma, sponsored by Chengdu Shangjin Nanfu Hospital. Primary endpoint: Objective response rate. Started Dec 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2400094102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094102.